- Market Capitalization, $K 132,831,008
- Shares Outstanding, K 2,527,226
- Annual Sales, $ 46,348 M
- Annual Income, $ 7,362 M
- 60-Month Beta 0.50
- Price/Sales 2.94
- Price/Cash Flow 9.59
- Price/Book 1.61
|Period||Period Low||Period High||Performance|
| || |
-2.70 (-4.85%)since 04/14/22
| || |
+0.18 (+0.33%)since 02/17/22
| || |
-0.44 (-0.83%)since 05/17/21
The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022. Stock up.
Advancing insulin technology promises a better patient experience.
Palm Beach, FL – May 11, 2022 – FinancialNewsMedia.com News Commentary – Diabetes and heart failure are closely linked. People with type 2 diabetes are two to four times more likely to develop heart...
Its late-stage pipeline is heavily weighted toward pandemic treatments.
These three pharma stocks each pay market-beating dividends to shareholders.
Regeneron (REGN) beats on Q1 earnings and sales record year-over-year growth on the solid performance of Dupixent and Eylea.
Regeneron's (REGN) first-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent.
SNY earnings call for the period ending March 31, 2022.
Seagen (SGEN) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates.
Biomarin Pharmaceutical's (BMRN) first-quarter earnings and sales beat estimates. BMRN also raises its financial guidance for 2022 Voxzogo sales by $10 million.
|Sanofi-Aventis S.A. ADR|
|ACWI Low Carbon Target Ishares MSCI ETF|
|World Ishares MSCI ETF|
|Intl Dividend Achievers Invesco ETF|
|EAFE ESG Optimized Ishares MSCI ETF|
|Advisorshares Doubleline Value Equity ETF|
|3rd Resistance Point||53.60|
|2nd Resistance Point||53.12|
|1st Resistance Point||52.84|
|1st Support Level||52.08|
|2nd Support Level||51.60|
|3rd Support Level||51.32|